Brian Helfand, MD

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    GoPath
    Date added:
    Date updated:
    09/20/2023
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    Blue Earth Diagnostics
    Date added:
    Date updated:
    09/20/2023
  • Attribution:
    Self
    Type of financial relationship:
    Meeting Participant or Lecturer (Oncology)
    Ineligible company:
    Blue Earth Diagnostics
    Date added:
    Date updated:
    09/20/2023
  • Attribution:
    Self
    Type of financial relationship:
    Other (Oncology)
    Ineligible company:
    Exact Sciences
    Date added:
    Date updated:
    09/20/2023
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    Ambry
    Date added:
    Date updated:
    09/20/2023
  • Attribution:
    Self
    Type of financial relationship:
    Meeting Participant or Lecturer (Oncology)
    Ineligible company:
    Exact Sciences
    Date added:
    Date updated:
    09/20/2023
  • Attribution:
    Self
    Type of financial relationship:
    Meeting Participant or Lecturer (Oncology)
    Ineligible company:
    Ambry Genetics
    Date added:
    Date updated:
    09/20/2023
Return to Global Advancements in Prostate Cancer: The Role of Genetic Testing and PARP Inhibitors (2022) - English